Rollins (ROL) Q2 Earnings and Revenues Surpass Estimates
ZACKS· 2025-07-23 22:16
Rollins (ROL) came out with quarterly earnings of $0.3 per share, beating the Zacks Consensus Estimate of $0.29 per share. This compares to earnings of $0.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +3.45%. A quarter ago, it was expected that this operator of Orkin and other pest and termine control services would post earnings of $0.22 per share when it actually produced earnings of $0.22, delivering no surprise.Over t ...
Waste Connections (WCN) Q2 Earnings and Revenues Surpass Estimates
ZACKS· 2025-07-23 22:16
Waste Connections (WCN) came out with quarterly earnings of $1.29 per share, beating the Zacks Consensus Estimate of $1.25 per share. This compares to earnings of $1.24 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +3.20%. A quarter ago, it was expected that this solid waste services provider would post earnings of $1.07 per share when it actually produced earnings of $1.13, delivering a surprise of +5.61%.Over the last four ...
SPAR Group, Inc. (SGRP) Group of Large Shareholders Demand the Directors Who Were Not Re-Elected to the Board of Directors at the 2024 Annual Meeting of Shareholders Held on June 12, 2025, Abide by the SGRP Bylaws
Newsfile· 2025-07-23 22:16
SPAR Group, Inc. (SGRP) Group of Large Shareholders Demand the Directors Who Were Not Re-Elected to the Board of Directors at the 2024 Annual Meeting of Shareholders Held on June 12, 2025, Abide by the SGRP BylawsJuly 23, 2025 6:16 PM EDT | Source: Robert G. BrownPalm Beach Gardens, Florida--(Newsfile Corp. - July 23, 2025) - ("SPAR") held its 2024 Annual Shareholders' Meeting on June 12, 2025 (the "Shareholder Meeting"), for the purposes, among other actions, to vote upon the election of cert ...
ASP Isotopes Inc. Announces Pricing of $60 Million Underwritten Registered Direct Offering of Common Stock
Globenewswire· 2025-07-23 22:15
WASHINGTON, July 23, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), today announced the pricing of an underwritten registered direct offering of 7,500,000 shares of its common stock at a price of $8.00 per share to a single fundamental institutional investor. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $60.0 million. The offering is expected to close on or abo ...
CSX (CSX) Beats Q2 Earnings Estimates
ZACKS· 2025-07-23 22:11
CSX (CSX) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.49 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +4.76%. A quarter ago, it was expected that this freight railroad would post earnings of $0.37 per share when it actually produced earnings of $0.34, delivering a surprise of -8.11%.Over the last four quarters, the company has ...
Hanover Bancorp, Inc. (HNVR) Misses Q2 Earnings and Revenue Estimates
ZACKS· 2025-07-23 22:11
Hanover Bancorp, Inc. (HNVR) came out with quarterly earnings of $0.33 per share, missing the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.11 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -42.11%. A quarter ago, it was expected that this company would post earnings of $0.51 per share when it actually produced earnings of $0.55, delivering a surprise of +7.84%.Over the last four quarters, the c ...
Churchill Downs (CHDN) Beats Q2 Earnings and Revenue Estimates
ZACKS· 2025-07-23 22:11
Churchill Downs (CHDN) came out with quarterly earnings of $3.1 per share, beating the Zacks Consensus Estimate of $3.03 per share. This compares to earnings of $2.89 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +2.31%. A quarter ago, it was expected that this racetrack operator and gambling company would post earnings of $1.08 per share when it actually produced earnings of $1.07, delivering a surprise of -0.93%.Over the l ...
T-Mobile (TMUS) Q2 Earnings and Revenues Beat Estimates
ZACKS· 2025-07-23 22:11
T-Mobile (TMUS) came out with quarterly earnings of $2.84 per share, beating the Zacks Consensus Estimate of $2.69 per share. This compares to earnings of $2.49 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +5.58%. A quarter ago, it was expected that this wireless carrier would post earnings of $2.45 per share when it actually produced earnings of $2.58, delivering a surprise of +5.31%.Over the last four quarters, the compan ...
SEI Investments (SEIC) Q2 Earnings Surpass Estimates
ZACKS· 2025-07-23 22:11
SEI Investments (SEIC) came out with quarterly earnings of $1.78 per share, beating the Zacks Consensus Estimate of $1.18 per share. This compares to earnings of $1.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +50.85%. A quarter ago, it was expected that this investment management firm would post earnings of $1.12 per share when it actually produced earnings of $1.17, delivering a surprise of +4.46%.Over the last four qu ...
Sarepta Therapeutics (SRPT) Tanks 36% After 3rd Patient Death, SRPT Securities Class Action Pending; Investors With Substantial Losses And Persons With Knowledge Encouraged To Contact Hagens Berman
GlobeNewswire News Room· 2025-07-23 22:07
SAN FRANCISCO, July 23, 2025 (GLOBE NEWSWIRE) -- On July 18, 2025, investors saw the price of their shares in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) collapse again – this time, shares closed down $7.89 (-36%) - after the company reported the death of a third patient who was being treated with one of its experimental gene therapy drugs. The development comes in the wake of a securities class action styled Dolgicera v. Sarepta Therapeutics, Inc. et al., No. 1:25-cv-05317 (S.D.N.Y.), which seeks to represen ...